US2004235837A1PendingUtilityA1
Method for treating fibrotic diseases or other indications IE
Priority: Jul 13, 2000Filed: Jun 21, 2004Published: Nov 25, 2004
Est. expiryJul 13, 2020(expired)· nominal 20-yr term from priority
A61P 9/04A61P 9/14A61P 9/10A61P 35/00A61P 3/10A61P 9/00A61P 9/12A61P 27/00A61P 25/02A61P 25/00A61P 29/00A61P 27/02A61P 1/02C07D 277/60A61K 31/427C07D 277/22A61P 17/00A61K 31/422A61P 15/10C07D 277/62A61P 19/00A61P 21/00A61K 31/421A61K 31/496A61K 31/4178A61P 19/02C07D 233/54A61K 31/541A61K 31/4164A61K 31/5377A61K 31/428A61K 31/501A61P 13/12A61K 31/426
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . A method of treating or ameliorating fibrotic disease, stiff vessel disease, myocardial infarct, cardiomyopathy, angina, restinosis, bladder elasticity, macular degeneration, amyotrophic lateral sclerosis, rheumatoid arthritis, bone resorption, dialysis, asthma, carpel tunnel, peridontal disease, sickle cell anemia, neoplastic disorders, limited joint mobility or erectile dysfunction in an animal, including a human, comprising administering an effective amount of (A) a compound of the formula I:
wherein
a. R 1 and R 2 are
1. independently selected from hydrogen, acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, (C 1 -C 3 )alkylenedioxy, allyl, amino, ω-alkylenesulfonic acid, carbamoyl, carboxy, carboxyalkyl, cycloalkyl, dialkylamino, halo, hydroxy, (C 2 -C 6 )hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid, alkylsulfonyl, alkylsulfinyl, alkylthio, trifluoromethyl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, 4-[C 6 or C 10 ]arylpiperidin-1-yl, 4-[C 6 or C 10 ]arylpiperazin-1-yl, Ar {wherein, consistent with the rules of aromaticity, Ar is C 6 or C 10 aryl or a 5- or 6-membered heteroaryl ring, wherein 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each heteroaryl ring can be fused to a benzene, pyridine, pyrimidine, pyridazine, pyrazine, or (1,2,3)triazine (wherein the ring fusion is at a carbon-carbon double bond of Ar)}, Ar-alkyl, Ar—O, ArSO 2 —, ArSO—, ArS—, ArSO 2 NH—, ArNH, (N—Ar)(N-alkyl)N—, ArC(O)—, ArC(O)NH—, ArNH—C(O)—, and (N—Ar)(N-alkyl)N—C(O)—, or together R 1 and R 2 comprise methylenedioxy; or
2. together with their ring carbons form a C 6 - or C 10 -aromatic fused ring system; or
3. together with their ring carbons form a C 5 -C 7 fused cycloalkyl ring having up to two double bonds including the fused double bond of the -olium or -onium containing ring, which cycloalkyl ring can be substituted by one or more of the group consisting of alkyl, alkoxycarbonyl, amino, aminocarbonyl, carboxy, fluoro, or oxo substituents; or
4. together with their ring carbons form a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each heteroaryl ring may be optionally substituted with one or more 1-pyrrolidinyl-, 4-[C 6 or C 10 ]arylpiperazin-1-yl, 4-[C 6 or C 10 ]arylpiperidin-1-yl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, halo or (C 1 -C 3 )alkylenedioxy groups; or
5. together with their ring carbons form a five to eight membered heterocycle, wherein the heterocycle consists of ring atoms selected from the group consisting of carbon, nitrogen, and S(O) n , where n=0, 1, or 2;
b. Z is
1. hydrogen, alkyl, Ar—CH 2 ;
2. a group of the formula —NR 3 R 4 , wherein R 3 and R 4 may be independently hydrogen, alkyl, Ar, or Ar-alkyl-;
3. a group of the formula —CH(OR 11 )R 12 , wherein R 11 is hydrogen, methyl, ethyl or CH 3 C(O)—; and R 12 is [C 1 to C 6 ]alkyl, Ar, or CO 2 R 13 wherein R 13 is hydrogen methyl or ethyl;
4. a group of the formula —C(CO 2 R 13 )(OR 11 )R 12
5. a group of the formula —CH 2 WAr, wherein W is —(C═O)— or —S(O) n — where n=1 or 2; or
6. a group of the formula —CH 2 C═C—R 14 , wherein R 14 is (C 1 -C 6 )alkyl;
c. Y is
1. amino, or
2. a group of the formula —CH(R 5 )—R 6 wherein
(a) R 5 is hydrogen, alkyl-, cycloalkyl-, alkenyl-, alkynyl-, aminoalkyl-, dialkylaminoalkyl-, (N—[C 6 or C 10 ]aryl)(N-alkyl)aminoalkyl-, piperidin-1-ylalkyl-, 1-pyrrolidinylalkyl, azetidinylalkyl, 4-alkylpiperazin-1-ylalkyl, 4-alkylpiperidin-1-ylalkyl, 4-[C 6 or C 10 ]arylpiperazin-1-ylalkyl, 4-[C 6 or C 10 ]arylpiperidin-1-ylalkyl, azetidin-1-ylalkyl, morpholin-4-ylalkyl, thiomorpholin-4-ylalkyl, piperidin-1-ylalkyl, [C 6 or C 10 ]aryl, or independently the same as R 6 ;
(b) R 6 is
(1) hydrogen, alkyl (which can be substituted by alkoxycarbonyl), alkenyl, alkynyl, cyano- or Rs, wherein Rs is a C 6 or C 10 aryl or a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or
(2) a group of the formula —W—R 7 , wherein R 7 is alkyl, alkoxy, hydroxy or Rs, wherein W is —C(═O)— or —S(O) n — where n=1 or 2;
(3) a group of the formula —W—OR wherein R 8 is hydrogen or alkyl,
(4) a group of the formula —CH(OH)Rs; or
(5) a group of the formula —W—N(R 9 )R 10 , wherein [a]R 9 is hydrogen and R 10 is an alkyl or cycloalkyl, optionally substituted by (i) [C 6 or C 10 ]aryl, or (ii) a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, said heteroaryl ring can be optionally substituted with one or more 1-pyrrolidinyl, 4-[C 6 or C 10 ]arylpiperazin-1-yl, 4-[C 6 or C 10 ]arylpiperidin-1-yl, azetidin-1-yl, and morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, halo or (C 1 -C 3 ) alkylenedioxy groups, or fused to a substituted phenyl or pyridine ring, wherein the ring fusion is at a carbon-carbon double bond of the heteroaryl ring, or (iii) a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or [b] R 9 is hydrogen or lower alkyl and R 10 is Ar; or [c] R 9 is hydrogen or lower alkyl, and R 10 is a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms are selected from the group consisting of oxygen, nitrogen and sulfur, said heterocycle; or [d] R 9 and R 10 are both alkyl groups; or [e] R 9 and R 10 together with N form a heterocycle containing 4-10 ring atoms which can incorporate up to one additional heteroatom selected from the group of N, O or S in the ring, wherein the heterocycle is optionally substituted with (C 6 — or C 10 )aryl, (C 6 — or C 10 )arylalkyl, or a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each such heteroaryl can be optionally substituted with one or more 1-pyrrolidinyl, 4-[C 6 or C 10 ]arylpiperazin-1-yl, 4-[C 6 or C 10 ]arylpiperidin-1-yl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, halo or (C 1 -C 3 )alkylenedioxy; or [f] R 9 and R 10 are both hydrogen; or
d. Q is N, O or S;
e. M is absent when Q is O or S;
f. M is alkyl, vinyl or allyl, or independently the same as Y; and
g. X is a pharmaceutically acceptable anion, or
(B) a pharmaceutically acceptable salt of the compound,
wherein aryl or Ar can be substituted with, in addition to any substitutions specifically noted, one or more substituents selected from the group consisting of acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, (C 1 -C 3 )alkylenedioxy, alkylsulfonyl, alkylsulfinyl, ω-alkylenesulfonic acid, alkylthio, allyl, amino, ArC(O)—, ArC(O)NH—, ArO—, Ar—, Ar-alkyl-, carboxy, carboxyalkyl, cycloalkyl, dialkylamino, halo, trifluoromethyl, hydroxy, (C 2 -C 6 )hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid, 1-pyrrolidinyl, 4-[C 6 or C 10 ]arylpiperazin-1-yl, 4-[C 6 or C 10 ]arylpiperidin-1-yl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl; and
wherein heterocycles, except those of Ar, can be substituted with, in addition to any substitutions specifically noted, acylamino, alkanoyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, alkylsulfonyl, alkylsulfinyl, alkylthio, amino, ArC(O)—, ArO—, Ar—, carboxy, dialkylamino, fluoro, fluoroalkyl, difluoroalkyl, hydroxy, mercapto, sulfamoyl, or trifluoromethyl.
2 . The method of claim 1 , comprising administering an effective amount of a compound of formula I, wherein Y is according to formula —CH(R 5 )R 6 .
3 . The method of claim 2 , comprising administering an effective amount of a compound of formula I, wherein Y is according to formula —CH(R 5 )—W—R 7 .
4 . The method of claim 2 , comprising administering an effective amount of a compound of formula I, wherein Y is according to formula —CH(R 5 )—W-Rs.
5 . The method of claim 1 , comprising administering an effective amount of a compound of formula I, wherein R 1 and R 2 together with their ring carbons form a C 6 - or C 10 -aromatic fused ring which can be substituted by one or more halo, amino, alkyl, sulfonic acid, alkylsulfonyl or ω-alkylenesulfonic acid groups, or a C 1 -C 3 alkylenedioxy group with the proviso that when Q is nitrogen R 1 and R 2 do not form a C 6 fused aromatic ring.
6 . The method of claim 1 , comprising administering an effective amount of a compound of the compound of formula I, wherein Q is S, and Y and Z are both —NH 2 .
7 . The method of claim 1 , comprising administering an effective amount of a compound of formula I, wherein
a. R 1 and R 2 are
1. independently selected from hydrogen, acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, (C 1 -C 3 )alkylenedioxy, allyl, ω-alkylenesulfonic acid, carbamoyl, carboxy, carboxyalkyl, cycloalkyl, halo, hydroxy, (C 2 -C 6 )hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid, alkylsulfonyl, alkylsulfinyl, alkylthio, trifluoromethyl, Ar {wherein, consistent with the rules of aromaticity, Ar is C 6 or C 10 aryl or a 5- or 6-membered heteroaryl ring, wherein 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each heteroaryl ring can be fused to a benzene, pyrimidine, pyridazine, pyrazine, or (1,2,3)triazine (wherein the ring fusion is at a carbon-carbon double bond of Ar)}, Ar-alkyl, Ar—O, ArSO 2 —, ArSO—, ArS—, ArSO 2 NH—, ArNH, (N—Ar)(N-alkyl)N—, ArC(O)—, ArC(O)NH—, ArNH—C(O)—, and (N—Ar)(N-alkyl)N—C(O)—; or
2. together with their ring carbons form a C 6 — or C 10 -aromatic fused ring system; or
3. together with their ring carbons form a C 5 -C 7 fused cycloalkyl ring having up to two double bonds including the fused double bond of the -olium or -onium containing ring, which cycloalkyl ring can be substituted by one or more of the group consisting of alkyl, alkoxycarbonyl, aminocarbonyl, carboxy, fluoro, or oxo substituents; or
4. together with their ring carbons form a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each heteroaryl ring may be optionally substituted with one or more halo or (C 1 -C 3 )alkylenedioxy groups; or
5. together with their ring carbons form a five to eight membered heterocycle, wherein the heterocycle consists of ring atoms selected from the group consisting of carbon, nitrogen, and S(O) n , where n=0, 1, or 2;
b. Z is
1. hydrogen, alkyl, Ar—CH 2 ;
2. a group of the formula —NR 3 R 4 , wherein R 3 and R 4 may be independently hydrogen, alkyl, Ar, or Ar-alkyl-;
3. a group of the formula —CH(OR 11 )R 12 , wherein R 11 is hydrogen, methyl, ethyl or CH 3 C(O)—; and R 12 is [C 1 to C 6 ]alkyl, Ar, or CO 2 R 13 wherein R 13 is hydrogen methyl or ethyl;
4. a group of the formula —C(CO 2 R 13 )(OR 11 )R 12
5. a group of the formula —CH 2 WAr, wherein W is —(C═O)— or —S(O) n — where n=1 or 2; or
6. a group of the formula —CH 2 C═C—R 14 , wherein R 14 is (C 1 -C 6 )alkyl;
c. Y is
1. amino, or
2. a group of the formula —CH(R 5 )—R 6 wherein
(a) R 5 is hydrogen or alkyl;
(b) R 6 is
(1) hydrogen, alkyl (which can be substituted by alkoxycarbonyl), alkenyl, alkynyl, cyano- or Rs, wherein Rs is a C 6 or C 10 aryl or a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or
(2) a group of the formula —W—R 7 , wherein R 7 is alkyl, alkoxy, hydroxy or Rs, wherein W is —C═O— or —S(O) n — where n=1 or 2;
(3) a group of the formula —W—OR 8 wherein R 8 is hydrogen or alkyl,
(4) a group of the formula —CH(OH)Rs; or
(5) a group of the formula —W—N(R 9 )R 10 , wherein [a]R 9 is hydrogen and R 10 is an alkyl or cycloalkyl, optionally substituted by (i) [C 6 or C 10 ]aryl, or (ii) a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, said heteroaryl ring can be optionally substituted with one or more halo or (C 1 -C 3 ) alkylenedioxy groups, or fused to a substituted phenyl, or (iii) a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or [b] R 9 is hydrogen or lower alkyl and R 10 is Ar; or [c] R 9 is hydrogen or lower alkyl, and R 10 is a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms are selected from the group consisting of oxygen, nitrogen and sulfur, said heterocycle; or [d] R 9 and R 10 are both alkyl groups; or [e] R 9 and R 10 together with N form a heterocycle containing 4-10 ring atoms which can incorporate up to one additional heteroatom selected from the group of N, O or S in the ring, wherein the heterocycle is optionally substituted with (C 6 - or C 10 )aryl, (C 6 - or C 10 )arylalkyl, or a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each such heteroaryl can be optionally substituted with one or more halo or (C 1 -C 3 )alkylenedioxy; or [f] R 9 and R 10 are both hydrogen; or
d. Q is N, O or S; e. M is absent when Q is O or S; f. M is alkyl, vinyl or allyl, or independently the same as Y; and g. X is a pharmaceutically acceptable anion, or (B) a pharmaceutically acceptable salt of the compound, wherein aryl or Ar can be substituted with, in addition to any substitutions specifically noted, one or more substituents selected from the group consisting of acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, (C 1 -C 3 )alkylenedioxy, alkylsulfonyl, alkylsulfinyl, ω-alkylenesulfonic acid, alkylthio, allyl, ArC(O)—, ArC(O)NH—, ArO—, Ar—, Ar-alkyl-, carboxy, carboxyalkyl, cycloalkyl, halo, trifluoromethyl, hydroxy, (C 2 -C 6 )hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid; and wherein heterocycles, except those of Ar, can be substituted with, in addition to any substitutions specifically noted, acylamino, alkanoyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylsulfonyl, alkylsulfinyl, alkylthio, ArC(O)—, ArO—, Ar—, carboxy, fluoro, fluoroalkyl, difluoroalkyl, hydroxy, mercapto, sulfamoyl, or trifluoromethyl.
8 . The method of claim 7 , comprising administering an effective amount of a compound of formula I, wherein Y is according to formula —CH(R 5 )R 6 .
9 . The method of claim 8 , comprising administering an effective amount of a compound of formula I, wherein Y is according to formula —CH(R 5 )—W—R 7 .
10 . The method of claim 8 , comprising administering an effective amount of a compound of formula I, wherein Y is according to formula —CH(R 5 )—W-Rs.
11 . The method of claim 7 , comprising administering an effective amount of a compound of the compound of formula I, wherein Q is S, Y and Z are both —NH 2 .
12 . The method of claim 1 , wherein the compound is 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium salt.
13 . The method of claim 12 , wherein the compound is 3-(2-phenyl-2-oxoethyl)4,5-dimethylthiazolium chloride.
14 . The method of claim 12 , wherein the compound is 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium bromide.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.